Infection

RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
A bridge to uncertainty? large #RCT of #baricitinib V #TNFi In Active #RA w #DVT/#VTE risk factor(s) Sl more VTE, #infection #SIE on #Bar NO increase #MACE Sl ⬆️#malignancy #VTE rate exceeded upper limit of a priori #CI So is this good news or not? #LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE

Links:

Janet Pope @Janetbirdope( View Tweet )
Some new #vaccination #recommendations #EULAR2026 @RheumNow https://t.co/j7cOJPpOcV https://t.co/VnGkFwTZ86

Links:

Janet Pope @Janetbirdope( View Tweet )
#EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL

Links:

Janet Pope @Janetbirdope( View Tweet )
TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
Dr. John Cush @RheumNow( View Tweet )
#EULAR2026 Recommendations: Immunization (new since 2011) - Vaccinate early regardless of dz acitiviry - HBV booster/passive if poor response - Yellow fever may be considered on individual basis - Avoid live vaccines (mostly) in newborn exposed in utero to biologic @RheumNow

Jiha Lee @JihaRheum( View Tweet )

#EULAR2026 #vaccination #guidelines ➡️be proactive ❎disease activity doesn’t matter ✅it is responsibility of #rheumatologist to discuss and update pt? @RheumNow @eular_org https://t.co/dRnHd9CThg

Links:

Janet Pope @Janetbirdope( View Tweet )
How to treat #RA-#ILD Similar to #IPF Occurs older men esp Smoking risk Vaccines Etc Philippe Dieude #HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF

Links:

Janet Pope @Janetbirdope( View Tweet )
Controversial #Rheumatoid #arthritis disease activity May not affect #ILD BUT affects #mortality level evidence +/- PHillippe Dieude said #Rx from RCTs #IS Ex #rituximab #antifibrotics #nintedanib #nerandomilast HOw to Treat RA-ILD June 5 #EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8

Links:

Janet Pope @Janetbirdope( View Tweet )
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated. Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067

Bella Mehta @bella_mehta( View Tweet )

Interesting poster #POS0939 from @SteZhao #EULAR2026 Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals 11,611 HLA-B27+ UK biobank Recall bias? Yes but self-reported exposure validated with primary care data @RheumNow https://t.co/VmxI3BW6FE

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up. Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh

Links:

Dr. John Cush @RheumNow( View Tweet )
EGPA https://t.co/zlquehIZQ6

Links:

Rheumatology update @aabdogafar( View Tweet )
Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
VACIMRA RCT in 249 RA pts on MTX were PCV13 vaccinated & continued or held MTX x 4wks. Best humoral responses w/ holding MTX x4wks with no clinical detriment over next 12 mos (remission, LDA, Xray outcomes) https://t.co/b6ByOYY0Fi https://t.co/XeJURKLpL8

Links:

Dr. John Cush @RheumNow( View Tweet )
30 yr Retrospective study of 1216 SLE hospitalizations in Barcelona - SLE flares & infections were most frequent. Hosp for infections signif. increased & in last 5yrs, exceeded Dz flares (34% vs. 26%). Younger pts had more flare hosp; older more infx hosp. Over time infx have https://t.co/TkUiXaoL1R
Dr. John Cush @RheumNow( View Tweet )
The safe/right choice is H. Zoster. You never fully eradicate invasive fungal or NTM infections. HBV is too risky to again use TNFi again. After H.zoster is Rx,there is evidence its safe to restart TNFi without risk of recurrence. Vagal N. Stim is the mechanistically same as

Dr. John Cush @RheumNow( View Tweet )

RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?

Dr. John Cush @RheumNow( View Tweet )

RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?

Dr. John Cush @RheumNow( View Tweet )

Immune-Mediated Inflammatory Diseases Following Uveitis A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID). https://t.co/NJI4369ygL https://t.co/6mHK8hYMeG

Links:

Dr. John Cush @RheumNow( View Tweet )
Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Advanced Practice Rheum

Safety of Biologics and Novel Agents

Jack Cush, MD
APR Safety Video Cover
Dr. Jack Cush reviews safety of biologics and novel agents.
Read Article
Advanced Practice Rheum

Steroids

Jack Cush, MD
STEROIDS COVER
In this Advanced Practice Rheum, Dr. Jack Cush reviews steroids.
Read Article

A Brief History of Rheumatoid Arthritis Mimics

Robert Schoen, MD, MBA
books history
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×